Stopping GLP-1s May Trigger Weight Regain and Heart Risk
Reports suggest discontinuing GLP-1 medications (like semaglutide/tirzepatide) often leads to meaningful weight regain and may worsen cardiometabolic risk facto...
#obesity medicine
Obesity medicine is making headlines as new reports highlight the risks of discontinuing GLP-1 medications, such as weight regain and worsened cardiometabolic health. With millions starting these drugs and insurers altering coverage, the topic offers a timely angle for content creators to explore the challenges of stop-start cycles and their impact on long-term health outcomes.
Content hooks for #obesity medicine
- If you stop GLP-1s, your biology doesn’t ‘stay fixed’—here’s what tends to happen next.
- The biggest GLP-1 myth: ‘Once I lose it, I’m cured.’
- Weight regain after Ozempic/Wegovy isn’t a willpower issue—let’s talk mechanisms.
Ready-to-post tweets
Quitting GLP-1s isn’t just “stopping a med.” For many, appetite returns + weight regain follows. The real question: what’s your maintenance plan (training, protein, follow-ups) BEFORE you stop?
Hot take: Obesity care keeps failing because we treat it like a 12-week project instead of a chronic condition.